

**FIGURE 1: CTLA-4 VLD-SPECIFIC OLIGONUCLEOTIDES**

[illegible]

**Figure 1 (con't'd)**

[illegible]

**Figure 1 (cont'd)**

CTLA-4 codon-change	5599	66	CC	CAGACCCCTggATggTCAGgTTCACCTggTTACCGCTggAggTgCCggTgCAgATggAATCATCCAg
CTLA-4 codon-change	5597	57		CACTTTgCAgATgTACAgACCggTATCCATggCACgCAGACCCCTggATggTCAggTT
CTLA-4 codon-change	5606	66		CAGCCATgACCgCATTCgTAAATAgACgCATAgATggTgCTATCCACTTTgCAgATgTACAgACC
CTLA-4 codon-change	5607	69		CTgggTACCgTTgCCgATgCCAGAAATCgTAgCCATAgCCACCggTggACAggCCATgACCgCATTCgTA
////////////////////	////////	////		////////////////////
////////////////////				////////////////////

<sup>1</sup> All oligonucleotides are described 5' to 3'.

<sup>2</sup> N represents combination of the four nucleotides

Figure 1 (cont'd)

Figure 2: Polynucleotide sequence of complete cDNA encoding human CTLA-4 and polypeptide sequence of the VLD of human CTLA-4.

A. Polynucleotide Encoding Human CTLA-4 cDNA

ATGGCTTGCC TTGGATTCA GGGGCACAAG GCTCAGCTGA ACCTGGCTGC CAGGACCTGG CCCTGCACTC TCCTGTTT... 80  
TCTTCTCTTC ATCCCTGTCT TCTGCAAGC AATGCACGTG GCCCAGCCTG CTGTGCTACT GSCCAGCAGC CGAGGCATCG... 160  
CCAGCTTTGT GTGTGAGTAT GCATCTCCAG GCAAAGCCAC TGAGGTCCGG GTGACAGTGC TTCGGCAGGC TGACAGCCAG... 240  
GTGACTGAAG TCTGTGCGGC AACCTACATG ACGGGGAATG AGTTGACCTT CCTAGATGAT TCCATCTGCA CGGGCACCTC... 320  
CAGTGGAAAT CAAGTGAACC TCACTATCCA AGGACTGAGG GCCATGGACA CGGGACTCTA CATCTGCAAG GTGGAGCTCA... 400  
TGTACCCACC GCCATACTAC CTGGGCATAG GCAACGGAAC CCAGATTAT GTAATTGATC CAGAACCCTG CCCAGATTCT... 480  
GACTTCCTCC TCTGGATCCT TGCAGCAGTT AGTTCGGGGT TGTCTTTTTA TAGCTTTCTC CTCACAGCTG TTTCTTTGAG... 560  
CAAAATGCTA AAGAAAGAA GCCCTCTTAC AACAGGGGTC TATGTGAAA TGCCCCCAAC AGAGCCAGAA TGTGAAAAGC... 640  
AATTTCAGCC TTATTTTATT CCCATCAATT GA ... 672

B. Polypeptide Sequence of Human CTLA-4 VLD

1	10	20	30	40	50	60	70	80
AMHVAQPAV	LASSRGIAS	F VCEYASPGK	A TEVRVTVL	RQ ADSQVTEV	CA ATYMMGNEL	F FLDDSICTG	T SSGNQVNL	I
90	100	110	115					
QGLRAMDTGL	YICKVELMY	P PPYLGIGN	G AQIV					

Figure 3: Phage display of CTLA-4 VLD STMs





Figure 4: Schematic representation of the somatostatin polypeptide.



8/15

Figure 5: Comparison of the HPLC profiles of affinity purified CTLA-4 VLD and CTLA-4-Som3 STM






Figure 6: Schematic diagram of CTLA-4 VLD CDR loop replacements.




Figure 7: HPLC profiles of affinity purified recombinant CTLA-4 STMs




Figure 8: Comparison by size exclusion HPLC analysis of affinity purified CTLA-4 VLD STM constructs synthesised using bacterial expression vector pGC or pPOW.




Figure 9: Size exclusion HPLC analysis of affinity purified CTLA-4 VLD STMs: Effect of Freeze/Thaw upon protein






Figure 10: Lysozyme binding characteristics of CTLA-4 anti-lysozyme construct 2V8


A



B



### Figure 11: Screening of CTLA-4 VLD Phagemid Library on Immobilised Sh Bleomycin



009007" 7F922960

338 W-04040510 2 FEB 8000

Figure 12: Screening of CTLA-4 VLD libraries in solution.

